Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Haft

Pulmonary Disease Richmond, VA Medical Doctor

NPI 1972529717 CMS profile 44227

6600 W Broad St Ste 300, Ste 300, Richmond, VA 23230

Open in the dashboard

General payments

$7,446

140 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$36,628 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Kenneth Haft of Richmond, VA is reported in the CMS Open Payments database as having received $7,446 across 140 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $36,628 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 74th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $493 26
2024 General $3,806 21
2023 General $343 18
2022 General $303 17
2021 General $1,393 17
2020 General $923 29
2019 General $187 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Haft
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Kenneth Haft were reported at $493. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Kenneth Haft Pulmonary Disease median Middle half National median
2019 $187 $377 $109–$1,340 $163
2020 $923 $230 $56–$907 $114
2021 $1,393 $269 $68–$1,072 $132
2022 $303 $390 $100–$1,457 $149
2023 $343 $419 $114–$1,659 $160
2024 $3,806 $476 $123–$1,818 $164
2025 $493 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Intuitive Surgical, Inc. $3,575 8 payments
  2. Paratek Pharmaceuticals, Inc. $1,186 3 payments
  3. Actelion Pharmaceuticals, Ltd $669 9 payments
  4. GlaxoSmithKline, LLC. $434 35 payments
  5. Amgen Inc. $220 11 payments
  6. AstraZeneca Pharmaceuticals LP $201 7 payments
  7. Insmed, Inc. $139 10 payments
  8. Genzyme Corporation $134 8 payments
  9. Grifols USA, LLC $116 6 payments
  10. Relypsa, Inc. $93 5 payments
  11. Other $678 38 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $2,534 3 payments
  2. Food and Beverage $2,270 127 payments
  3. Travel and Lodging $1,483 9 payments
  4. Consulting Fee $1,160 1 payment
Products named General payments · program years 2019–2025
  1. Da Vinci Surgical System $3,575 8 payments
  2. NUZYRA $1,186 3 payments
  3. TRELEGY ELLIPTA $276 22 payments
  4. TEZSPIRE $205 10 payments
  5. DUPIXENT $174 10 payments
  6. Arikayce $139 10 payments
  7. NUCALA $132 11 payments
  8. BREZTRI $122 2 payments
  9. Prolastin-C Liquid $116 6 payments
  10. ACTHAR $79 3 payments
  11. Other $946 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

4,218

Median for Pulmonary Disease: 936

Drug cost

$1,373,540

Median for Pulmonary Disease: $487,987

Branded share of claims

68.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 493 $480,752
Spiriva Respimat Tiotropium Bromide Brand 156 $145,954
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 125 $118,204
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 147 $105,405
Breo Ellipta Fluticasone/Vilanterol Brand 144 $91,010
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 111 $86,344
Xarelto Rivaroxaban Brand 51 $51,274
Spiriva Handihaler Tiotropium Bromide Brand 49 $49,612
Symbicort Budesonide/Formoterol Fumarate Brand 98 $39,347
Incruse Ellipta Umeclidinium Bromide Brand 56 $34,366

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 75 billing codes

Paid by Medicare

$799,008

Of which drugs: $567,161

Medicare patients

995

Average age 76

Services billed

27,384

614 women, 381 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
COPD 54%
Ischemic heart disease 43%
Diabetes 34%
Depression 31%
Chronic kidney disease 30%
Heart failure 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 54 7,065 $209,914
Injection, mepolizumab, 1 mg J2182 Office 33 6,400 $151,402
Injection, tezepelumab-ekko, 1 mg J2356 Office 13 9,240 $131,430
Injection, benralizumab, 1 mg J0517 Office 13 540 $70,790
Vaccine for influenza for injection into muscle 90653 Office 12 12 $882
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 26 412 $94
Injection, methylprednisolone sodium succinate, up to 40 mg J2920 Office 12 24 $59

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zemaira
  • Relypsa, Inc. $73
$73 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $47
$47 493 —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $28
$28 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $22
$22 125 —
Arikayce
  • Insmed, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record